Shopping Cart
- Remove All
Your shopping cart is currently empty
KY-1044
😃Good
Catalog No. T81968Cas No. 2489390-15-8
Alias SAR 445256, Alomfilimab
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 monoclonal antibody targeting the inducible costimulatory receptor (ICOS). It selectively depletes cells with high ICOS expression via antibody-dependent cellular cytotoxicity (ADCC) mediated by FcγRIIIa engagement and acts as a costimulatory molecule for cells with lower ICOS levels, such as CD8+ T Effector cells, through FcγR-dependent clustering. KY-1044 leverages varying ICOS expression levels across T-cell subsets to enhance the intratumoral immune milieu and reinvigorate antitumor immune responses [1].
KY-1044
KY-1044
😃Good
Catalog No. T81968Alias SAR 445256, AlomfilimabCas No. 2489390-15-8
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 monoclonal antibody targeting the inducible costimulatory receptor (ICOS). It selectively depletes cells with high ICOS expression via antibody-dependent cellular cytotoxicity (ADCC) mediated by FcγRIIIa engagement and acts as a costimulatory molecule for cells with lower ICOS levels, such as CD8+ T Effector cells, through FcγR-dependent clustering. KY-1044 leverages varying ICOS expression levels across T-cell subsets to enhance the intratumoral immune milieu and reinvigorate antitumor immune responses [1].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | Inquiry | Backorder | |
| 5 mg | Inquiry | Backorder |
Bulk & Custom
Add to Cart
Questions
View MoreContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 monoclonal antibody targeting the inducible costimulatory receptor (ICOS). It selectively depletes cells with high ICOS expression via antibody-dependent cellular cytotoxicity (ADCC) mediated by FcγRIIIa engagement and acts as a costimulatory molecule for cells with lower ICOS levels, such as CD8+ T Effector cells, through FcγR-dependent clustering. KY-1044 leverages varying ICOS expression levels across T-cell subsets to enhance the intratumoral immune milieu and reinvigorate antitumor immune responses [1]. |
| In vitro | KY-1044 (Alomfilimab; SAR 445256; 0-100ng/mL; 4 hours) induces potent ADCC-mediated killing in human NK cells expressing hICOS at an effector-to-target cell ratio of 5:1, with an EC50 value of 5.6 pmol/L [1]. |
| In vivo | KY-1044 (Alomfilimab; SAR 445256; 10 mg/kg; intraperitoneal injection; bi-weekly for 3 weeks) as a monotherapy, effectively inhibited tumor growth in lymphoma/multiple myeloma models with mIgG2a (effector function-enabled). In syngeneic mouse tumor models, KY-1044 depleted ICOS high Treg cells and enhanced the ratio of tumor-infiltrating T Eff to Treg cells, leading to increased IFNγ and TNFα secretion by Eff cells [1]. |
| Alias | SAR 445256, Alomfilimab |
| Cas No. | 2489390-15-8 |
Storage & Solubility Information
| Storage | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy KY-1044 | purchase KY-1044 | KY-1044 cost | order KY-1044 | KY-1044 in vivo | KY-1044 in vitro
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.